

ADVANCES IN NUTRITIONAL RESEARCH

VOLUME 5

Edited by Harold H. Draper

Advances in

Nutritional Research

Volume 5

Edited by Harold H. Draper

*University of Guelph
Guelph, Ontario, Canada*

Plenum Press · New York and London

The Library of Congress cataloged the first volume of this title as follows:

Advances in nutritional research. v.1-

New York, Plenum Press, c1977-

1 v, ill. 24 cm.

Key title: Advances in nutritional research, ISSN 0149-9483

1. Nutrition--Yearbooks.

QP141.A1A3

613.2/05

78-640645

ISBN 0-306-41095-8

© 1983 Plenum Press, New York

A Division of Plenum Publishing Corporation

233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Contributors

Joyce L. Beare-Rogers, Bureau of Nutritional Sciences, Food Directorate, Health Protection Branch, Department of National Health and Welfare, Ottawa K1A 0L2, Canada

Robert H. Bower, Hyperalimentation Unit, University of Cincinnati Medical Center, Cincinnati, Ohio 45267

Tammy M. Bray, Department of Nutrition, University of Guelph, Guelph, Ontario N1G 2W1, Canada

James R. Carlson, Department of Animal Sciences, Washington State University, Pullman, Washington 99164

Frank Chytil, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

J. W. T. Dickerson, Department of Biochemistry, University of Surrey, Surrey GU2 5XH, United Kingdom

Jørn Dyerberg, Department of Clinical Chemistry, Aalborg Hospital, Section North, DK-9000 Aalborg, Denmark

Josef E. Fischer, Department of Surgery, University of Cincinnati Medical Center, Cincinnati, Ohio 45267

Gene R. Herzberg, Department of Biochemistry, Memorial University of Newfoundland, St. John's, Newfoundland A1B 3X9, Canada

Kaj Anker Jørgensen, Department of Clinical Chemistry, Aalborg Hospital, Section North, DK-9000, Denmark

Russell J. Merritt, Childrens Hospital of Los Angeles, University of Southern California, School of Medicine, Los Angeles, California 90027

David E. Ong, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

Nancy J. Rothwell, Department of Physiology, St. George's Hospital Medical School, Tooting, London SW17 0RE, England

Barry Shane, Department of Biochemistry, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205

Frank R. Sinatra, Childrens Hospital of Los Angeles, University of Southern California, School of Medicine, Los Angeles, California 90027

Gary A. Smith, Childrens Hospital of Los Angeles, University of Southern California, School of Medicine, Los Angeles, California 90027

Michael J. Stock, Department of Physiology, St. George's Hospital Medical School, Tooting, London SW17 0RE, England

E. L. Robert Stokstad, Department of Nutritional Sciences, University of California, Berkeley, California 94720

Preface

Volume 5 of *Advances in Nutritional Research* reflects a strong current interest in the relationship between nutrition and disease. The impact of disease on nutritional status is described for hepatic encephalopathy and cancer and for several ailments of hospitalized children. The impact of nutrition on disease is illustrated using the examples of retinol in tumorigenesis, vitamins A and E in inflammatory lung disease, fatty acids in atherogenesis and obesity, and folate in megaloblastic anemia. The contents will be of particular interest to clinicians and to students of nutritional biochemistry.

Contents

Chapter 1. Nutritional Management of Hepatic Encephalopathy...	1
<i>Robert H. Bower and Josef E. Fischer</i>	
1. Introduction.....	1
2. The Nature of Hepatic Encephalopathy.....	2
2.1. The Ammonia Concept.....	2
2.2. The Amino Acid Neurotransmitter Concept.....	3
3. Nutritional Support in Hepatic Insufficiency.....	6
3.1. Therapeutic Implications.....	6
3.2. Therapeutic Options.....	6
4. Experiments in Animals.....	7
5. Experience with Patients in Hepatic Encephalopathy.....	7
5.1. Acute Hepatic Encephalopathy.....	7
5.2. Chronic Hepatic Encephalopathy.....	9
References.....	9
 Chapter 2. Cellular Retinol- and Retinoic Acid-Binding Proteins...	 13
<i>Frank Chytil and David E. Ong</i>	
1. Introduction.....	13
2. Cellular Retinol- and Retinoic Acid-Binding Proteins.....	13
2.1. Detection.....	14
2.2. Characteristics.....	15
3. Binding Proteins in Cultured Cells.....	19
4. Binding Proteins in Tumors.....	23
4.1. Binding Proteins in Experimental Tumors.....	23
4.2. Binding Proteins in Human Tumors.....	23
References.....	26

Chapter 3. Nutrition and 3-Methylindole-Induced Lung Injury	31
<i>James R. Carlson and Tammy M. Bray</i>	
1. Introduction	31
2. Acute Bovine Pulmonary Edema and Emphysema	33
3. Tryptophan-Induced Acute Pulmonary Edema and Emphysema	35
4. Effect of 3MI on the Lungs	37
5. Mechanism of Action of 3MI	38
5.1. Direct Effects of 3MI	38
5.2. The Role of Metabolism in Pulmonary Injury	40
6. Organ(s) Responsible for the Formation of Toxic Metabolites	44
7. Sources of 3MI and Possible Risk to Man	45
8. Formation of Reactive Intermediates by the MFO System	47
9. The Role of Nutrition in 3MI-Induced Lung Injury	49
References	51
Chapter 4. Platelets and Atherosclerosis	57
<i>Kaj Anker Jørgensen and Jørn Dyerberg</i>	
1. Introduction	57
2. Platelets and Atherogenesis	57
2.1. The Platelet-Derived Mitogenic Factor	57
2.2. Development of the Atherosclerotic Lesion	58
2.3. Platelets and Experimental Atherosclerosis	59
3. Thromboxane, Prostacyclin, and Platelet Function	59
3.1. Stable Prostaglandins and Platelets	59
3.2. Prostaglandin Endoperoxides and Thromboxane	60
3.3. Prostacyclin	61
3.4. The Exchangeability of Endoperoxides between Platelets and Endothelial Cells	62
3.5. Summary	64
4. Prostacyclin, Thromboxane, and Atherosclerosis	64
4.1. Lipid Peroxides and Atherosclerosis	64
4.2. Prostacyclin Production of Atherosclerosis-Resistant Blood Vessels	64
4.3. Prostacyclin and Thromboxane in Experimental Atherosclerosis	65
4.4. Prostacyclin and Thromboxane in Diabetes Mellitus, Hypercholesterolemia, and the Nephrotic Syndrome	65
5. Dietary Manipulation of Hemostatic Prostanoids	66
5.1. Dihomo- γ -linolenic Acid	66
5.2. Eicosapentaenoic Acid	66

6. Final Remarks	68
References	68
 Chapter 5. Nutritional Support of the Hospitalized Child	77
<i>Russell J. Merritt, Frank R. Sinatra, and Gary A. Smith</i>	
1. Introduction	77
2. Malnutrition in Hospitalized Patients	77
3. Nutritional Assessment	78
4. Therapeutic Techniques	80
5. The Preterm Neonates	85
6. Intractable Diarrhea of Infancy	88
7. Short-Bowel Syndrome	90
8. Inflammatory Bowel Disease	92
9. Cancer	94
References	96
 Chapter 6. Nutrition of the Cancer Patient	105
<i>J. W. T. Dickerson</i>	
1. Introduction	105
2. Effects of Cancer on Nutrition	105
2.1. Malnutrition and the Anorexia-Cachexia Syndrome	105
2.2. Effects of Cancer on Taste	109
2.3. Fat Metabolism	110
2.4. Plasma Albumin	111
2.5. Effects of Tumors in Specific Organs	112
2.6. Effects of Cancer on Specific Nutrients	114
3. Effects of the Treatment of Cancer on Nutrition	121
3.1. General Considerations	121
3.2. Surgery	122
3.3. Radiotherapy and Chemotherapy	124
3.4. Effects of Drugs on Specific Nutrients	126
3.5. Nutritional Support in the Cancer Patient	126
References	127
 Chapter 7. The Interrelationships among Folate, Vitamin B ₁₂ , and Methionine Metabolism	133
<i>Barry Shane and E. L. Robert Stokstad</i>	
1. Background	133
2. Metabolism of Folate	134
2.1 Amino Acid Interconversions	135

2.2.	Thymidylate Synthesis	137
2.3.	Purine Biosynthesis	138
2.4.	Role of Folylpolyglutamates	139
2.5.	Regulation of One-Carbon Metabolism.	141
3.	Methyl Trap Hypothesis.	142
3.1.	Serum Folate Levels	143
3.2.	Metabolism of Histidine, Serine, and Formate.	144
3.3.	Folate Uptake and Metabolism	145
3.4.	Methionine Synthetase	148
3.5.	Folylpolyglutamate Synthetase	149
3.6.	Deoxyuridine Suppression Test	150
4.	Effect of Methionine on Folate Metabolism	152
5.	Molecular Basis of Megaloblastosis	157
6.	Effect of Nitrous Oxide	158
7.	Effect of Thyroid Function	160
8.	Concluding Remarks	161
	References	163

Chapter 8. *trans* and Positional Isomers of Common Fatty Acids. . 171
Joyce L. Beare-Rogers

1.	Introduction	171
2.	Monoenoic Fatty Acids	172
2.1.	Distribution	173
2.2.	Studies in Animals	175
2.3.	Studies in Man	182
3.	Polyenoic Fatty Acids	184
3.1.	<i>cis, trans</i> -Isomers	185
3.2.	<i>trans, trans</i> -Isomers	186
4.	Energy Production	188
4.1.	Mitochondrial Oxidation	189
4.2.	Peroxisomal Oxidation	190
5.	Biological Implications	192
	References	192

Chapter 9. Diet-Induced Thermogenesis 201
Nancy J. Rothwell and Michael J. Stock

1.	Energy Balance and Thermogenesis	201
1.1.	Diet-Induced Thermogenesis	201
1.2.	Mechanisms of DIT	203

2.	Genetic Influences on Thermogenesis	204
2.1.	Experimental Animals	204
2.2.	Wild Animals	205
2.3.	Genetic Influences on Brown Fat	206
3.	Effects of Dietary Composition on DIT	209
3.1.	Fat and Carbohydrate	209
3.2.	Alcohol	211
4.	Effects on Environment on DIT	211
4.1.	Temperature	211
4.2.	Housing Conditions	212
4.3.	Meal Pattern	212
4.4.	Hypoxia	213
4.5.	Season	213
5.	Effects of Age on DIT	215
	References	216

Chapter 10. The Influence of Dietary Fatty Acid Composition on Lipogenesis 221

Gene R. Herzberg

1.	The Pathway of Lipogenesis	221
2.	Dietary Fat and Lipogenesis	225
2.1.	Dietary Fat Inhibits Hepatic Lipogenesis	225
2.2.	Dietary Fat Inhibits Adipose Tissue Lipogenesis	228
2.3.	Inhibition by Dietary Fat Is Not Due to Decreased Carbohydrate Intake	228
2.4.	Fatty Acid Composition of the Diet Regulates the Synthesis of Lipid	229
3.	Enzyme Adaptations to Fat Feeding	239
3.1.	Acetyl-CoA Carboxylase	239
3.2.	Fatty Acid Synthetase	240
3.3.	Pyruvate Dehydrogenase	241
3.4.	ATP Citrate Lyase	242
3.5.	Malic Enzyme	242
3.6.	The Phosphogluconate Pathway	243
4.	Esterification Reactions	244
4.1.	Synthesis <i>in Vivo</i> or <i>in Vitro</i>	244
4.2.	Enzyme Adaptations	245
5.	Conclusions	245
	References	247

Index	255
-----------------	-----

Chapter 1

Nutritional Management of Hepatic Encephalopathy

Robert H. Bower and Josef E. Fischer

1. Introduction

Hepatic insufficiency is a common consequence of critical illness. The liver's multiplicity of processes and its position astride the portal vein, where it receives nutrients and prepares them for distribution to the periphery, make it the central organ in any metabolic scheme. It is precisely this central role which causes the derangements of these processes in hepatic insufficiency to affect all phases of body economy.

The ability of the liver to regenerate is well known. Therapy of the failing liver is aimed at support to allow time for regeneration to occur. Among the factors which are known to influence regeneration (e.g., triiodothyronine, adrenal corticosteroids, growth hormone, insulin, glucagon, "ileal factor" and nutrition), none is more easily manipulated by the physician than nutrition (Fig. 1). The provision of appropriate nutrients not only helps to sustain hepatic function but promotes regeneration as well.

Although the metabolism of all nutrients is deranged in hepatic failure, intolerance to protein most severely limits nutritional support. The provision of adequate protein for protein synthesis is necessary to keep the muscular, respiratory, metabolic, host defense, and immunologic functions of the body intact, as well as to meet the additional demands for repair of injured tissues. However, the

Robert H. Bower • Hyperalimentation Unit, University of Cincinnati Medical Center, Cincinnati, Ohio 45267. Josef E. Fischer • Department of Surgery, University of Cincinnati Medical Center, Cincinnati, Ohio 45267. This work was supported in part by USPHS Grant AM-25347.




Fig. 1. Among the factors which influence hepatic regeneration, nutrition is the most easily manipulated.

administration of adequate protein to sustain these processes in the patient with hepatic failure is often accompanied by encephalopathy.

Nutritional management of hepatic encephalopathy is aimed at providing sufficient protein to the patient without precipitating encephalopathy. Such an approach requires an understanding of the cause of hepatic encephalopathy.

2. The Nature of Hepatic Encephalopathy

2.1. The Ammonia Concept

The clinical presentation of hepatic encephalopathy may be subtle and varied. Although mania and psychosis are usually prominent, associated disturbances, such as errors in judgment, reversal of day/night rhythm, and mood changes, and postural disorders, such as asterixis, may be less readily apparent. The classic explanation of hepatic encephalopathy has involved ammonia behaving as a "toxin." However, the variety of clinical presentation is unlikely to be the result of a single toxin in the presence of otherwise normal physiology. It is

equally unlikely that derangements in brain energy metabolism would produce such a varied clinical presentation.

According to the classical toxin hypothesis, ammonia, liberated by bacteria in the gut, exerts its toxic influence on the central nervous system (CNS) due to lack of inactivation by the liver. It is often overlooked that ammonia is a metabolite which may arise from protein catabolism, deamination of amino acids by muscle, and endogenous production in the gut, not necessarily from gut bacteria (Hoyumpa *et al.*, 1979). Moreover, there is dissociation of blood ammonia level and the grade of hepatic encephalopathy. Rationalization of this lack of correlation is based on imperfections in measurement. Nonetheless, neither arterial nor venous ammonia levels correlate well with the grade of encephalopathy. Furthermore, the toxicity of ammonia does not correlate with its concentration. Methionine sulfoximine increases the concentration of ammonia in the CNS through inhibition of glutamine synthesis but decreases its toxicity (Warren and Schenker, 1964). In contrast, monoamine oxidase inhibitors decrease blood ammonia concentration but increase its toxicity and the grade of encephalopathy (Dawson and Sherlock, 1957). These observations suggest that ammonia is unlikely to be the sole etiologic agent of hepatic encephalopathy.

Zieve has proposed a synergism hypothesis. According to this theory, in the presence of underlying liver disease, encephalopathy and coma are the result of the synergistic effects of coma-producing toxins and endogenous metabolic abnormalities. Ammonia is considered to be central to the pathogenesis with mercaptans, fatty acids, and endogenous metabolic abnormalities creating an environment in which smaller accumulations of any single substance may produce encephalopathy. Although isolated experiments have implicated some of these pathogenetic factors individually, direct evidence that these biochemical abnormalities are responsible for the abnormalities is lacking (Zieve, 1981).

2.2. The Amino Acid Neurotransmitter Concept

A decade ago, Fischer and Baldessarini proposed that under conditions of decreased hepatic function and shunting of blood around the liver, amines or their amino acid precursors escape inactivation by the liver and flood the central and peripheral aminergic nervous system. In the CNS, these compounds produce the symptoms of hepatic encephalopathy and basal ganglia postural disorders such as asterixis (Fischer and Baldessarini, 1971). Cardiovascular effects such as the high output-low peripheral resistance congestive failure syndrome and the hepatorenal syndrome associated with redistribution of renal blood flow are secondary to loss of catecholaminergic tone in the peripheral autonomic nervous system (Fischer and Baldessarini, 1971; Fischer and James, 1972). This hypothesis was based on observations on experimental animals in hepatic encephalopathy, which displayed imbalances in the central, primitive, and generally midline aminergic system. Norepinephrine and striatal dopamine were decreased while

increases were noted in β -hydroxyphenylethanolamine neuromodulators or neuroregulators, octopamine and phenylethanolamine, and indoleamines, including serotonin (Baldessarini and Fischer, 1973; Dodsworth *et al.*, 1974).

The aminergic nervous system is not arranged in classical anatomic fashion. Rather than ending in classic synaptic relationships, its axons and dendrites end free in the matrix, yet no neuron seems to be more than 30 Å from a nerve ending of the aminergic system. This system has feedback circuits which ramify throughout the CNS (Dismukes, 1977). These extensive ramifications and feedback circuits suggest a neuromodulatory or neuroregulatory role for this system rather than a classical action (Dismukes, 1977).

The monoamine imbalance in the aminergic nervous system in hepatic encephalopathy is due not to the amines themselves entering the brain but to disorders in the metabolism of their precursor amino acids, including phenylalanine, tyrosine, and tryptophan. These aromatic amino acids, along with the branched-chain amino acids (BCAA) valine, leucine, and isoleucine, as well as histidine and methionine, are members of the large neutral amino group. Members of this group compete for a single transport system (System L) which mediates their entry across the blood-brain barrier (Wade and Katzman, 1975). Neutral amino acid disturbances in plasma during encephalopathy include increased aromatic amino acids (phenylalanine, tyrosine, free tryptophan, and methionine) with decreased BCAA (Iber *et al.*, 1957; Svec and Freeman, 1949; Fischer *et al.*, 1974). The deranged pattern of plasma amino acids is the result of hormonal imbalances including a relative lack of insulin and a relative excess of glucagon. Increased levels of epinephrine and adrenocortical steroids, due to their decreased catabolism, augment the hyperglucagonemia to cause sustained gluconeogenesis (Eigler *et al.*, 1979). In addition, failure of energy production in the form of decreased glucose and ketone body production from the failing liver results in further catabolism. The BCAA tend to be consumed locally by muscle and fat for energy production. The aromatic amino acids, which are catabolized primarily by the liver, accumulate in plasma. The resultant excess of aromatic amino acids and scarcity of BCAA in plasma give rise to excessive concentrations of aromatic amino acids within the brain (Rosen *et al.*, 1977; Soeters and Fischer, 1976).

However, abnormalities in the observed concentrations of neutral amino acids within the brain cannot be explained on the basis of plasma competitor ratios alone. Using the technique of Fernstrom and Faller (1978), the brain concentration of amino acids could be predicted by calculating the plasma competitor ratios. The equation accurately predicted the concentration of brain aromatic amino acids in control animals. However, in animals with portacaval anastomosis (PCA), the neutral amino acid concentration exceeded the predicted values in an orderly way (Fig. 2). There is recent evidence to suggest a derangement in the blood-brain barrier and that transport of the neutral amino acids is selectively increased (Cremer *et al.*, 1977). From experiments on animals fol-




Fig. 2. The observed brain concentration of neutral amino acids, using phenylalanine as an example, is compared with the predicted brain concentration of phenylalanine as calculated from the brain influx rate from the equation of Fernstrom and Faller (1978). The open circles represent sham-operated animals, and the closed circles represent animals which have undergone PCA. Note that the sham-operated animals fall within 1 standard deviation of the predicted brain concentration of phenylalanine as calculated from the brain influx rate. The shunted animals are all above the line but follow another linear function far above that which holds true for the sham-operated animals.

lowing end-to-side PCA and on isolated brain capillaries from normal animals and those with PCA, it appears that ammonia and its intracerebral metabolite, glutamine, are involved in the blood-brain transport abnormality (James *et al.*, 1978; Cardelli-Cangiano *et al.*, 1981). Exchange for glutamine appears to be responsible for the increased velocity of transport of the neutral amino acids into the brain. Ammonia appears to contribute to encephalopathy indirectly by raising the brain concentration of neutral amino acids and altering neurotransmitter metabolism, rather than by exerting any direct toxic effect (James *et al.*, 1979; Jeppsson *et al.*, 1980).

In clinical practice, catabolism, sepsis, starvation, gastrointestinal bleeding, or overdiuresis may result in an increase in aromatic amino acids, a decrease in BCAA or both. The cirrhotic patient is thus sensitized so that any stress will increase the neurotransmitter disorder and increase the tendency toward encephalo-

lopathy. The nutritional therapy of hepatic encephalopathy should attempt to decrease the level of aromatic amino acids and to increase BCAA in plasma in order that the patient may tolerate increased amounts of protein without an exacerbation of hepatic encephalopathy.

3. Nutritional Support in Hepatic Insufficiency

3.1. Therapeutic Implications

As has been mentioned earlier, the provision of adequate nutrition is the most easily manipulated of the factors which influence hepatic regeneration. Protein is the most important component of nutrition, not only for repair of the failing liver but for the maintenance of nonspecific host resistance (Alexander *et al.*, 1980). Unfortunately, administration of adequate protein results in encephalopathy. Therefore, despite abnormalities in the metabolism of all nutrients, it is encephalopathy which most severely limits nutritional support of the patient in hepatic failure.

Paradoxically, a diet devoid of protein mimics the amino acid imbalances which are seen with a high-protein diet. Gluconeogenesis results in the release of amino acids from muscle and the resultant accumulation of aromatic amino acids. In rats which had undergone PCA, an inverse relationship between the amount of protein infused and the concentration of aromatic amino acids in plasma and brain was observed. Plasma phenylalanine and tyrosine as well as brain octopamine, a false neurotransmitter, decreased as nitrogen balance became positive (Rosen *et al.*, 1978). Even small amounts of protein may be sufficient to stimulate anabolism and to incorporate the aromatic amino acids into protein.

3.2. Therapeutic Options

It becomes apparent that modest amounts of protein are preferable to a protein-free diet. Nearly 50% of patients with impaired but stable hepatic function with little or no encephalopathy may tolerate up to 60–80 g of oral protein or the equivalent of one of the commercially available amino acid solutions. Those patients who are intolerant of protein and become encephalopathic are candidates for special amino acid mixtures.

BCAA-enriched mixtures offer a number of theoretical advantages. Provision of BCAA may decrease the efflux of amino acids across the muscle–plasma membrane (Buse and Reid, 1975). BCAA may be utilized directly for energy by the periphery. Although they normally provide only 5 to 8% of the total energy output, they may provide a greater percentage under conditions of energy deficit, such as decreased production of glucose and ketone bodies in hepatic failure. The BCAA are the principle competitors of the aromatic amino acids for